Cannabinoid Derived Pharmaceuticals Industry Review Summit

Cannabinoid derived pharmaceuticals have faced many challenges in their development. Cannabis prohibition being the original and biggest obstruction .. Read more to progress. Now the industry has started facing new, more acute challenges like finding suitable patient populations and designing robust trials, working with regulators around the world with varying attitudes towards cannabis, selecting the most pharmacologically appropriate synthetic or phytocannabinoid possible just to name a few. Along with the challenges COVID-19 has created over the past months many of these other challenges have been facing the industry for years. finding suitable patient populations and designing robust trials, working with regulators around the world with varying attitudes towards cannabis, selecting the most pharmacologically appropriate synthetic or phytocannabinoid possible. Introducing the first Cannabinoid Derived Pharmaceuticals Industry Review Summit, taking place virtually 19th – 21st January. Attending online will give you access to the same opportunities as a physical attendee through our purpose-built online conference platform.